Ballard Spahr IP Attorneys Advise DRI Healthcare on $179M Pharmaceutical Royalty Acquisition
November 06, 2024
November 06, 2024
PHILADELPHIA, Pennsylvania, Nov. 6 -- Ballard Spahr, a law firm, issued the following news release:
Ballard Spahr Intellectual Property attorneys advised DRI Healthcare Trust on patent and regulatory matters in acquiring a synthetic royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals for an aggregate purchase price of up to $179 million. The transaction closed November 4.
The purchase price for the synthetic roya . . .
Ballard Spahr Intellectual Property attorneys advised DRI Healthcare Trust on patent and regulatory matters in acquiring a synthetic royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals for an aggregate purchase price of up to $179 million. The transaction closed November 4.
The purchase price for the synthetic roya . . .